CIK 0001563880
- Non-accelerated filer
- Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 450834299
- Phone
- +1 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 6 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-09 | Richard King Mellon Foundation 10% owner | Other acquisition | +24,341 | 247,157 | ||
| 2019-05-09 | Richard King Mellon Foundation 10% owner | Purchase | +100,000 | $10.00 | $1.0M | 347,157 |
| 2019-05-09 | Richard King Mellon Foundation 10% owner | Conversion · Series C Preferred Stock | −1,908,450 | 0 | ||
| 2019-05-09 | VANLENT ANNE Director | Conversion | +20,983 | 20,983 | ||
| 2019-05-09 | VANLENT ANNE Director | Purchase | +5,000 | $10.00 | $50K | 25,983 |
| 2019-05-09 | VANLENT ANNE Director | Conversion · Series A Preferred Stock | −107,977 | 0 | ||
| 2019-05-09 | VANLENT ANNE Director | Conversion · Series C Preferred Stock | −47,807 | 0 | ||
| 2019-05-09 | Lundbeckfond Invest A/S 10% owner | Conversion | +776,544 | 776,544 | ||
| 2019-05-09 | Lundbeckfond Invest A/S 10% owner | Purchase | +375,000 | $10.00 | $3.8M | 1,151,544 |
| 2019-05-09 | Lundbeckfond Invest A/S 10% owner | Conversion · Series C Preferred Stock | −6,849,315 | 0 | ||
| 2019-05-09 | Drake Debra A 10% owner | Conversion | +52,141 | 52,141 | ||
| 2019-05-09 | Drake Debra A 10% owner | Conversion | +10,399 | 10,399 | ||
| 2019-05-09 | Drake Debra A 10% owner | Conversion · Series A Preferred Stock | −58,153 | 0 | ||
| 2019-05-09 | Drake Debra A 10% owner | Conversion · Series A Preferred Stock | −75,000 | 0 | ||
| 2019-05-09 | Drake Debra A 10% owner | Conversion · Series C Preferred Stock | −376,023 | 0 | ||
| 2019-05-09 | SCIASCIA THOMAS Chief Medical Officer | Conversion | +17,118 | 193,724 | ||
| 2019-05-09 | SCIASCIA THOMAS Chief Medical Officer | Conversion · Series A Preferred Stock | −109,015 | 0 | ||
| 2019-05-09 | SCIASCIA THOMAS Chief Medical Officer | Conversion · Series C Preferred Stock | −13,410 | 0 | ||
| 2019-05-07 | Mathers Edward T Director | Grant or award · Stock Option (right to buy) | +23,684 | 23,684 |
Page 21 of 21 · 419 trades